Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Impact of Weekly Administration of Rifapentine and Isoniazid on Steady State Pharmacokinetics of Tenofovir Alafenamide in Healthy Volunteers

Trial Profile

Impact of Weekly Administration of Rifapentine and Isoniazid on Steady State Pharmacokinetics of Tenofovir Alafenamide in Healthy Volunteers

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Isoniazid (Primary) ; Rifapentine (Primary) ; Tenofovir alafenamide (Primary) ; Pyridoxine
  • Indications Hepatitis B; HIV infections; HIV-1 infections; Tuberculosis
  • Focus Pharmacokinetics
  • Acronyms YODA
  • Most Recent Events

    • 21 Jul 2021 Planned End Date changed from 30 Aug 2022 to 31 Dec 2022.
    • 21 Jul 2021 Planned primary completion date changed from 30 Aug 2021 to 31 Dec 2021.
    • 24 Jul 2020 Planned End Date changed from 30 Aug 2021 to 30 Aug 2022.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top